Do not stop memantine without asking the prescriber why it was started and whether it still provides meaningful benefit. If stopping is appropriate, request a gradual dose reduction, a monitoring plan, and clear criteria for restarting it. Memantine is a medicine used to manage symptoms of certain dementias. It does not help every person, and evidence about what happens after discontinuation remains limited.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Does the diagnosis still support treatment?
- Is memantine still helping?
- Is there a sound reason to deprescribe?
- Could the dose or another problem explain the decline?
- What should the stopping plan include?
Does the diagnosis still support treatment?
Ask the prescriber to confirm the diagnosis, dementia stage, and original treatment goal. U.S. labeling indicates memantine for moderate-to-severe dementia of the Alzheimer's type, not every condition that causes cognitive decline, according to the current DailyMed label. Guidance can also depend on other dementia medicines.
NICE recommends memantine alone for severe Alzheimer's disease, or moderate Alzheimer's when cholinesterase inhibitors are unsuitable. It also recommends considering memantine alongside an existing cholinesterase inhibitor in moderate or severe Alzheimer's disease. Evidence for Parkinson's disease dementia and dementia with Lewy bodies is limited or uncertain. The prescriber should not assume that Alzheimer's evidence applies to these conditions without qualification.
Is memantine still helping?
Benefit may appear as slower deterioration rather than visible improvement. Ask whether records show changes in daily activities, cognition, behaviour, mood, or the amount of help the person needs.
A 2019 Cochrane review found small benefits in cognition, daily activities, and behaviour or mood in moderate-to-severe Alzheimer's disease. It found probably no benefit in mild Alzheimer's disease. Useful questions include:.
- What outcome were we hoping to preserve or improve?
- Has that outcome changed since treatment began?
- Could continuing provide meaningful benefit at the current stage?
- How will we distinguish a medication effect from the dementia's progression?
Is there a sound reason to deprescribe?
Deprescribing means reducing and stopping a medicine through a planned clinical process. It may be reasonable when there is no ongoing benefit, the indication is inappropriate, adverse effects are intolerable, doses are often missed, or meaningful future benefit is unlikely. Terminal illness may also shift the balance toward comfort and fewer medicines.
The person's wishes and the care partner's observations should remain part of the decision, especially when benefits are subtle. Ask the prescriber to explain which reason applies. "The dementia has become severe" is not automatically enough, because some evidence supports continued treatment in advanced Alzheimer's disease.
Could the dose or another problem explain the decline?
Before attributing new confusion or reduced function to dementia, review timing, dose, kidney function, and other medicines. Common adverse reactions listed for memantine include dizziness, headache, confusion, and constipation. The label recommends 5 mg twice daily for severe renal impairment.
It also warns that alkaline urine can raise memantine levels. Ask whether the current dose remains appropriate and whether a medication or health change could have altered exposure. Report concrete observations rather than saying the person is "worse." Examples include a new fall, missed meals, increased agitation, inability to dress, or confusion that began after a dose change.
What should the stopping plan include?
Evidence specifically about stopping memantine is weak. Limited observational findings cannot prove that discontinuation causes worsening, while a small trial in extremely severe Alzheimer's combined memantine and donepezil results and could not isolate memantine's withdrawal effect. The Canadian Consensus Conference guidance recommends gradual reduction and restarting treatment if stopping appears to cause clinically meaningful deterioration in cognition, function, behaviour, or overall condition.
Earlier guidance suggests watching for decline for one to three months after tapering. Before the first reduction, agree on: Keep a brief daily record using observable measures, such as dressing assistance, conversations, sleep disruption, agitation, or participation in meals. Contact the prescriber promptly if several meaningful changes emerge after a dose reduction rather than waiting for the planned appointment.
- The taper steps and who will supervise them
- A baseline description of cognition, function, behaviour, and mood
- The dates for follow-up during the next one to three months
- The changes that should prompt an earlier call
- Who will decide whether to restart memantine
